Lycia Therapeutics (LYCA) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.72 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYCA | MAZE |
|---|---|---|
| Share price | $33.07 | $31.37 |
| Market cap | $1.72B | $1.72B |
| 1-day change | +4.09% | -3.27% |
| YTD return | — | -24.28% |
| 1-year return | — | -13.49% |
| EPS (TTM) | $-1.04 | $-2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-131.12M |
| 52-week high | $36.49 | $53.65 |
| 52-week low | $22.19 | $21.95 |
| Distance from 52-week high | -9.37% | -41.53% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +99.11% |
| Average volume | 432.72K | 737.14K |
| Shares outstanding | 52.09M | 54.68M |
| Employees | 31 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lycia Therapeutics
LYCA stock →Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
LYCA vs MAZE FAQ
Which is bigger, Lycia Therapeutics or Maze Therapeutics?
Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.72B for Maze Therapeutics (MAZE).
Are Lycia Therapeutics and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.